期刊文献+

卡培他滨联用滋补汤对一线化疗后气血两虚证晚期结直肠癌治疗的效果 被引量:1

原文传递
导出
摘要 目的研究在一线化疗后气血两虚证晚期结直肠癌患者中应用滋补汤联合卡培他滨维持治疗的临床效果。方法选取2013年6月—2017年6月太康县人民医院收治的72例一线化疗后气血两虚证晚期结直肠癌患者,按照随机数字表分为观察组和对照组,每组36例。对照组行卡培他滨维持治疗,观察组采用滋补汤联合卡培他滨维持治疗,观察分析两组总有效率、中医症状积分、生活质量评分及不良反应发生率。结果观察组一线化疗后气血两虚证晚期结直肠癌患者中医症状积分(16.87±0.35)分显著低于对照组的(24.54±1.11)分,生活质量评分(68.22±4.33)分、总有效率55.55%均高于对照组(50.54±4.36)分、30.55%,差异均有统计学意义(P<0.05)。结论将滋补汤联合卡培他滨维持治疗应用在一线化疗后气血两虚证晚期结直肠癌患者中效果显著,可改善患者临床症状,提高生活质量。
作者 张新昌
出处 《慢性病学杂志》 2020年第6期859-860,共2页 Chronic Pathematology Journal
  • 相关文献

参考文献8

二级参考文献57

  • 1权红.浅谈方和谦自拟“滋补汤”治疗虚劳[J].中国中医药信息杂志,2006,13(2):80-81. 被引量:4
  • 2徐飚,王建明.胃癌流行病学研究[J].中华肿瘤防治杂志,2006,13(1). 被引量:159
  • 3沈琳,马冬.晚期结直肠癌使用FOLFOX4或奥沙利铂断断-续续模式的FOLFOX7(OPTIMOX1)的随机临床研究[J].循证医学,2006,6(5):259-262. 被引量:47
  • 4De Gramont A, Figer A, Seymour M, et al. Leucovorin and Fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].J Clin Oncol, 2000,18 (16) : 2938-2947.
  • 5Sanoff H K, Sargent D J, Campbell M Data and Prognostic Factor Analysis Irinotecan Combinations for Advanced N9741 [J]. J Clin Oncol, 2008,26(35) E, et al. Five-Year of Oxaliplatin and Colorectal Cancer: 5721-5727.
  • 6Cheeseman S L, Joel S P, Chester J D, et al. A "modified de Gramont" regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer [ J ]. Br J Cancer, 2002,87 (4) : 393-399.
  • 7Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [J]. J Clin Oncol, 2005, 23 (36) : 9441-9442.
  • 8Novello S, Bruzzi P, Barone C. Phase 111 study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. Ann Oncol [J]. 2007,18(5) :903-908.
  • 9Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Finalresuhs of OPTIMOX2, a large randomized phase ]I study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study [J]. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2007,25(18S) :4013.
  • 10Chibaudel B, Maindrauh-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study [J].J Clin Oncol, 2009,27 (34) : 5727-5733.

共引文献138

同被引文献20

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部